You are here: Industry Insights > Chagas Disease

News List

FDA Approves Lampit for Chagas Disease in Pediatric Patients americanpharmaceuticalreview
August 25, 2020
The U.S. Food and Drug Administration (FDA) approved Lampit (nifurtimox) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg).
US FDA approves Lampit for the treatment of Chagas disease in children pharmaceutical-business-review
August 12, 2020
Bayer announced that the United States Food and Drug Administration (FDA) has approved Lampit (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease ...
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy worldpharmanews
March 19, 2019
At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor.
WHO to shift focus on eliminating Chagas disease biospectrum
November 20, 2018
Up to now, control and prevention strategies for Chagas disease largely relied on the early detection and treatment of infected newborns and siblings of pregnant women.
FDA Approves First U.S. Treatment for Chagas Disease pharmaceutical-technology
August 31, 2017
The U.S. Food and Drug Administration granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United States for the treatment of Chagas disease.